Phase 3 Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with endometrial cancer (any type except neuroendocrine tumors, carcinosarcoma, or endometrial sarcoma) that has come back or continued to grow, confirmed by laboratory testing of tissue or cells.
- People who have received at least 1 but no more than 3 prior rounds of treatment for their cancer.
- People whose prior treatment included both a platinum-based chemotherapy and an immunotherapy drug called a PD-(L)1 inhibitor (these may have been given separately or together).
- People whose cancer came back more than 12 months after finishing platinum-based chemotherapy may need to have received platinum-based chemotherapy again for the returning cancer, unless the treating doctor has documented a medical reason why that was not possible (confirm with trial site for details on exceptions).
- People whose cancer has been confirmed on scans to have grown or spread after their most recent treatment.
Who may not be able to join:
- People who have previously received a type of treatment called an antibody-drug conjugate that contains a topoisomerase 1 inhibitor.
- People who have, or have had, another cancer in addition to their endometrial cancer, unless that other cancer carries a very low risk of spreading or causing death, has been fully treated, or has been in complete remission for 3 or more years (specific exceptions apply — confirm with trial site).
- People with active cancer spread to the brain or the lining of the brain and spinal cord, although people whose brain metastases have already been treated and have been stable for at least 4 weeks, with no new or growing spots and no longer taking steroids or anti-seizure medications for at least 7 days, may still be considered (confirm with trial site).
- People who have been hospitalised due to a bowel blockage recently, have symptoms of a bowel blockage, or whose scans show a bowel blockage at the time of screening.
- People who currently require nutrition delivered directly into the bloodstream (intravenous nutrition) may need special review by the trial medical team to determine whether participation is possible (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Study Official, Genmab
Phone: +4570202728
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression-free Survival (PFS) per Response Criteria in Solid Tumors (RECIST) v1.1, as Determined by Blinded Independent Central Review (BICR); Overall Survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.